Table 2.
Baseline characteristics for each DMT group
|
No treatment n = 14 |
Glatiramer acetate n = 11 |
Interferons n = 7 | Dimethyl fumarate n = 23 | Teriflunomide n = 11 | Fingolimod n = 18 | Ocrelizumab n = 25 | Natalizumab n = 18 | Alemtuzumab n = 10 | Cladribine n = 2 | p value | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female sex, n (%) | 9 (64.3) | 8 (72.7) | 5 (71.4) | 17 (73.9) | 7 (63.6) | 11 (61.1) | 16 (64.0) | 14 (77.8) | 8 (80.0) | 1 (50.0) | 0.968 |
| Age, years | 50.1 (14.9) | 46.6 (14.9) | 35.4 (11.4) | 43.3 (12.3) | 58.8 (6.6) | 42.7 (11.9) | 40.2 (13.2) | 38.3 (7.9) | 38.2 (5.9) | 42.5 | < 0.001 |
| EDSS score, median [IQR] | 1.0 [0.0–1.0] | 1.0 [0.0–1.5] | 1.0 [0.5–2.0] | 1.0 [0.0–2.0] | 2.0 [1.0–3.5] | 2.5 [1.0–4.0] | 2.0 [1.5–3.5] | 2.0 [1.0–3.5] | 2.5 [1.5–3.5] | 1.0 | 0.030 |
| MS course, n (%) | |||||||||||
|
Relapsing Progressive |
10 (71.4) 4 (28.6) |
9 (81.8) 2 (18.2) |
7 (100) 0 |
22 (95.7) 1 (4.3) |
10 (90.9) 1 (9.1) |
16 (88.9) 2 (11.1) |
19 (76.0) 6 (24.0) |
18 (100) 0 |
10 (100) 0 |
2 (100) 0 |
0.149 |
| Any side effect, n (%) | 11 (78.6) | 7 (63.6) | 7 (100) | 18 (78.3) | 8 (72.7) | 8 (44.4) | 12 (48.0) | 15 (83.3) | 5 (50.0) | 1 (50.0) | 0.036 |
All values are reported as mean (standard deviation) unless indicated otherwise
EDSS Expanded Disability Status Scale, IQR interquartile range, MS multiple sclerosis